Esterberg E, Iyer S, Nagar SP, Davis KL, Tannir NM. Real-world treatment patterns and clinical outcomes among patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2024 Apr;22(2):115-125.e. doi: 10.1016/j.clgc.2023.09.009
Bellmunt J, Chang J, Pavilack-Kirker M, Cappelleri JC, Costa N, Esterberg E, Kearney M, Hitchens A, Candrilli SD, Ajmera M. Evaluating real-world characteristics of patients with advanced urothelial carcinoma eligible for avelumab maintenance therapy: a multi-country retrospective medical chart review. Clin Genitourin Cancer. 2023 Aug;21(4):459-66. doi: 10.1016/j.clgc.2023.03.011
Stattin P, Westerberg M, Franck Lissbrant I, Hjalm-Eriksson M, Kjellman A, Ullen A, Vassilev Z, Sandstrom P, Weinrib R, Martinez D, Garcia de Albeniz Martinez X. Real world outcomes in patients with metastatic, castration-resistant prostate cancer treated with radium-223 in routine clinical practice in Sweden. Clin Genitourin Cancer. 2022 Sep 9;S1558-7673(22):00194-X. doi: 10.1016/j.clgc.2022.09.002
Morgans A, Grewal S, Hepp Z, Fuldeore R, Odak S, Macahilig C, Shillington A, Sonpavde G. Clinical and patient-reported outcomes of advanced urothelial carcinoma following discontinuation of pd-1/l1 inhibitor therapy. Clin Genitourin Cancer. 2022 Aug 5. doi: 10.1016/j.clgc.2022.08.002
Nguyen Thi Nhan P, Van Toan D, Que Huong T, Minh Nguyet D, Thanh Dao T, Minh Tri L, Khac Minh T, Hoc TP Y. 3D-pharmacophore modeling and its application on allosteric inhibitors of rac serin/threonin protein kinase AKT1. Journal of Ho Chi Minh City Pharmacy Association. 2018;22(S1):380-8.
White MV, Silvia S, Hollis K, Wooddell M, Hogue S. Differences in anaphylaxis-related risks by school grade level: findings from the EpiPen4Schools® survey. Poster presented at the 2015 ASCIA Conference; September 2015. Adelaide, Australia. [abstract] Intern Med J. 2015 Sep 3; 45(Suppl 4):3. doi: 10.1111/imj.12869